Bank of New York Mellon Corp Sells 56,213 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Bank of New York Mellon Corp trimmed its position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 22.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 193,315 shares of the company’s stock after selling 56,213 shares during the period. Bank of New York Mellon Corp owned approximately 0.35% of Voyager Therapeutics worth $1,096,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC increased its position in Voyager Therapeutics by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock worth $6,316,000 after purchasing an additional 6,740 shares during the last quarter. Erste Asset Management GmbH purchased a new stake in shares of Voyager Therapeutics during the 3rd quarter valued at about $6,192,000. Massachusetts Financial Services Co. MA lifted its holdings in shares of Voyager Therapeutics by 19.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 171,856 shares of the company’s stock valued at $1,005,000 after acquiring an additional 28,333 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Voyager Therapeutics by 2.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 137,477 shares of the company’s stock worth $804,000 after acquiring an additional 3,473 shares in the last quarter. Finally, Barclays PLC increased its stake in Voyager Therapeutics by 55.8% during the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock worth $612,000 after acquiring an additional 37,398 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Price Performance

Voyager Therapeutics stock opened at $3.91 on Tuesday. The stock has a market cap of $215.86 million, a price-to-earnings ratio of 5.51 and a beta of 0.99. The firm has a 50-day moving average of $4.62 and a two-hundred day moving average of $5.71. Voyager Therapeutics, Inc. has a 1 year low of $3.56 and a 1 year high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.24). Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The company had revenue of $4.39 million for the quarter, compared to the consensus estimate of $16.58 million. During the same period in the prior year, the firm posted $1.25 EPS. Research analysts expect that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

VYGR has been the subject of several analyst reports. StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group reduced their target price on shares of Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th. Wells Fargo & Company set a $10.00 price target on shares of Voyager Therapeutics and gave the stock an “overweight” rating in a research note on Wednesday, March 12th. Finally, Citigroup started coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Voyager Therapeutics has a consensus rating of “Buy” and a consensus price target of $14.86.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.